Ms. Carter has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. Prior to co-founding Quoin, Ms. Carter held various positions with Innocoll, Inc., including president of Innocoll Pharmaceuticals and executive vice president of business development and corporate affairs of Innocoll, Inc. She also served as vice president of business development of the drug delivery division of West Pharmaceuticals, and she has held executive positions at Eurand and Fuisz Technologies (Biovail). Ms. Carter earned her MBA from Wharton School of Business, University of Pennsylvania, and a B.S. in Chemistry from the College of William and Mary.
Rare diseases are only rare if you don’t live with one.®
Subscribe to Email Alerts
Sign up for alerts to stay up to date on Quoin Pharmaceuticals.
Latest News:
Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies
Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic...
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results
– Private Placement Financing of Up to $105.3 Million Closed in October 2025 to Fund Operations and R&D – Sally Lawlor Appointed CFO to Support Commercialization and Financial Operations – Orphan Drug Designation Awarded by FDA to QRX003 for Netherton Syndrome –...